Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ELV Stock Forecast

Elevance Health stock forecast is as follows: an average price target of $538.74 (represents a 34.45% upside from ELV’s last price of $400.70) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

ELV Price Target

The average price target for Elevance Health (ELV) is $538.74 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $643.00 to $335.00. This represents a potential 34.45% upside from ELV's last price of $400.70.

ELV Analyst Ratings

Buy

According to 13 Wall Street analysts, Elevance Health's rating consensus is 'Buy'. The analyst rating breakdown for ELV stock is 0 'Strong Buy' (0.00%), 12 'Buy' (92.31%), 1 'Hold' (7.69%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Elevance Health Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 21, 2024	David Windley	Jefferies	$529.00	$430.77	22.80%	32.02%
Oct 21, 2024	Whit Mayo	Leerink Partners	$515.00	$430.77	19.55%	28.53%
Oct 18, 2024	Sarah James	Raymond James	$485.00	$432.53	12.13%	21.04%
Oct 18, 2024	Ben Hendrix	RBC Capital	$478.00	$444.35	7.57%	19.29%
Oct 18, 2024	David MacDonald	Truist Financial	$520.00	$444.35	17.02%	29.77%
Oct 16, 2024	Michael Ha	Robert W. Baird	$625.00	$483.87	29.17%	55.98%
Jul 18, 2024	Ben Hendrix	RBC Capital	$585.00	$502.06	16.52%	45.99%
Jul 15, 2024	David MacDonald	Truist Financial	$620.00	$535.54	15.77%	54.73%
Jun 24, 2024	Erin Wright	Morgan Stanley	$643.00	$534.42	20.32%	60.47%
May 29, 2024	Michael Ha	Robert W. Baird	$649.00	$505.52	28.38%	61.97%

Row per page

Go to

The latest Elevance Health stock forecast, released on Oct 21, 2024 by David Windley from Jefferies, set a price target of $529.00, which represents a 22.80% increase from the stock price at the time of the forecast ($430.77), and a 32.02% increase from ELV last price ($400.70).

Elevance Health Price Target by Period

	1M	3M	12M
# Anlaysts	2	6	15
Avg Price Target	$522.00	$525.33	$576.93
Last Closing Price	$400.70	$400.70	$400.70
Upside/Downside	30.27%	31.10%	43.98%

In the current month, the average price target of Elevance Health stock is $522.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 30.27% increase as opposed to Elevance Health's last price of $400.70. This month's average price target is down -0.63% compared to last quarter, and down -9.52% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 21, 2024	Jefferies	Buy	Buy	Hold
Oct 21, 2024	Leerink Partners	Outperform	Outperform	Hold
Oct 18, 2024	UBS	Buy	Buy	Hold
Oct 18, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Oct 18, 2024	Wells Fargo	Buy	Buy	Hold
Oct 18, 2024	Stephens	Underperform	Underperform	Hold
Oct 18, 2024	RBC Capital	Outperform	Outperform	Hold
Oct 10, 2024	Barclays	Overweight	Overweight	Hold
Aug 19, 2024	Wells Fargo	Buy	Buy	Hold

Row per page

Go to

Elevance Health's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave ELV a "Buy" rating, the same as its previous rate.

Elevance Health Financial Forecast

Elevance Health Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$42.65B	$42.85B	$43.67B	$42.17B	$39.93B	$39.94B	$38.63B	$38.09B	$36.58B	$35.82B	$33.85B	$32.38B	$31.82B	$31.16B	$29.26B	$29.62B	$27.41B	$26.67B
Avg Forecast	$51.06B	$51.44B	$50.56B	$49.14B	$47.89B	$47.97B	$46.83B	$45.55B	$44.90B	$43.47B	$42.99B	$42.49B	$42.19B	$42.76B	$41.64B	$40.92B	$39.77B	$39.29B	$37.91B	$37.39B	$36.50B	$35.35B	$33.13B	$32.97B	$30.90B	$29.86B	$29.39B	$28.69B	$27.07B	$25.89B
High Forecast	$52.88B	$53.28B	$52.36B	$50.89B	$49.60B	$49.68B	$48.50B	$47.10B	$46.31B	$43.47B	$42.99B	$42.49B	$42.82B	$44.29B	$43.12B	$42.38B	$41.19B	$39.29B	$37.91B	$37.39B	$36.50B	$35.35B	$33.13B	$32.97B	$30.90B	$29.86B	$29.39B	$28.69B	$27.07B	$25.89B
Low Forecast	$48.72B	$49.09B	$48.25B	$46.89B	$45.70B	$45.78B	$44.69B	$42.81B	$43.29B	$43.47B	$42.99B	$42.49B	$41.13B	$40.81B	$39.73B	$39.05B	$37.95B	$39.29B	$37.91B	$37.39B	$36.50B	$35.35B	$33.13B	$32.97B	$30.90B	$29.86B	$29.39B	$28.69B	$27.07B	$25.89B
# Analysts	6	6	12	11	10	9	8	13	14	9	6	6	12	9	9	9	5	5	5	5	6	6	6	6	10	10	10	10	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.00%	1.05%	1.03%	1.00%	1.02%	1.02%	1.02%	1.00%	1.01%	1.02%	0.98%	1.03%	1.04%	1.00%	1.03%	1.01%	1.03%

Elevance Health's average Quarter revenue forecast for Mar 24 based on 6 analysts is $42.49B, with a low forecast of $42.49B, and a high forecast of $42.49B. ELV's average Quarter revenue forecast represents a -0.36% decrease compared to the company's last Quarter revenue of $42.65B (Dec 23).

Elevance Health EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	6	12	11	10	9	8	13	14	9	6	6	12	9	9	9	5	5	5	5	6	6	6	6	10	10	10	10	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$449.00M	$32.73B	$34.53B	$3.33B	$1.84B	$2.81B	$2.75B	$2.90B	$1.97B	$2.56B	$2.86B	$2.65B	$1.09B	$895.00M	$3.64B	$2.55B	$1.53B	$1.98B
Avg Forecast	$3.12B	$3.14B	$3.09B	$3.00B	$2.93B	$2.93B	$2.86B	$2.78B	$2.74B	$2.66B	$2.63B	$3.31B	$2.58B	$2.61B	$2.54B	$3.01B	$2.16B	$2.09B	$2.02B	$2.73B	$1.94B	$1.88B	$1.76B	$2.44B	$1.64B	$1.59B	$1.56B	$2.55B	$1.44B	$1.38B
High Forecast	$3.23B	$3.26B	$3.20B	$3.11B	$3.03B	$3.04B	$2.96B	$2.88B	$2.83B	$2.66B	$2.63B	$3.97B	$2.62B	$2.71B	$2.64B	$3.61B	$2.59B	$2.09B	$2.02B	$3.28B	$1.94B	$1.88B	$1.76B	$2.93B	$1.64B	$1.59B	$1.56B	$3.06B	$1.44B	$1.38B
Low Forecast	$2.98B	$3.00B	$2.95B	$2.87B	$2.79B	$2.80B	$2.73B	$2.62B	$2.65B	$2.66B	$2.63B	$2.64B	$2.51B	$2.49B	$2.43B	$2.40B	$1.73B	$2.09B	$2.02B	$2.19B	$1.94B	$1.88B	$1.76B	$1.96B	$1.64B	$1.59B	$1.56B	$2.04B	$1.44B	$1.38B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.17%	12.53%	13.57%	1.11%	0.85%	1.34%	1.36%	1.06%	1.02%	1.36%	1.62%	1.08%	0.66%	0.56%	2.33%	1.00%	1.07%	1.43%

6 analysts predict ELV's average Quarter EBITDA for Mar 24 to be $3.31B, with a high of $3.97B and a low of $2.64B. This is 636.21% upper than Elevance Health's previous annual EBITDA (Dec 23) of $449.00M.

Elevance Health Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	6	12	11	10	9	8	13	14	9	6	6	12	9	9	9	5	5	5	5	6	6	6	6	10	10	10	10	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$856.00M	$1.30B	$1.86B	$1.99B	$949.00M	$1.62B	$1.65B	$1.80B	$1.13B	$1.51B	$1.79B	$1.67B	$551.00M	$222.00M	$2.28B	$1.52B	$934.00M	$1.18B
Avg Forecast	$1.38B	$2.28B	$2.78B	$2.91B	$1.28B	$2.04B	$2.35B	$2.40B	$927.55M	$2.25B	$2.33B	$2.06B	$1.30B	$1.97B	$2.05B	$1.87B	$1.24B	$1.67B	$1.81B	$1.70B	$1.19B	$1.49B	$1.48B	$1.54B	$590.93M	$962.07M	$2.04B	$1.52B	$906.26M	$1.12B
High Forecast	$1.45B	$2.38B	$2.91B	$3.04B	$1.34B	$2.13B	$2.46B	$3.12B	$1.54B	$2.26B	$2.33B	$2.47B	$1.32B	$2.06B	$2.14B	$2.25B	$1.49B	$1.67B	$1.81B	$2.04B	$1.19B	$1.49B	$1.48B	$1.84B	$590.93M	$962.07M	$2.04B	$1.83B	$906.26M	$1.12B
Low Forecast	$1.30B	$2.14B	$2.62B	$2.74B	$1.20B	$1.92B	$2.21B	$1.87B	$678.69M	$2.25B	$2.33B	$1.65B	$1.29B	$1.85B	$1.93B	$1.50B	$994.69M	$1.67B	$1.81B	$1.36B	$1.19B	$1.49B	$1.48B	$1.23B	$590.93M	$962.07M	$2.04B	$1.22B	$906.26M	$1.12B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.66%	0.66%	0.91%	1.06%	0.76%	0.97%	0.91%	1.06%	0.94%	1.01%	1.21%	1.08%	0.93%	0.23%	1.12%	1.00%	1.03%	1.05%

Elevance Health's average Quarter net income forecast for Mar 24 is $2.06B, with a range of $1.65B to $2.47B. ELV's average Quarter net income forecast represents a 140.77% increase compared to the company's last Quarter net income of $856.00M (Dec 23).

Elevance Health SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	6	12	11	10	9	8	13	14	9	6	6	12	9	9	9	5	5	5	5	6	6	6	6	10	10	10	10	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.80B	$4.56B	$4.51B	$4.27B	$4.34B	$4.22B	$3.95B	$3.82B	$3.92B	$4.32B	$5.30B	$4.05B	$3.78B	$3.50B	$3.42B
Avg Forecast	$2.16B	$2.18B	$2.14B	$2.08B	$2.03B	$2.03B	$1.98B	$1.93B	$1.90B	$1.84B	$1.82B	$4.96B	$1.78B	$1.81B	$1.76B	$4.51B	$4.62B	$5.59B	$5.40B	$4.10B	$5.20B	$5.03B	$4.72B	$3.62B	$4.40B	$4.25B	$4.18B	$3.78B	$3.85B	$3.69B
High Forecast	$2.24B	$2.25B	$2.21B	$2.15B	$2.10B	$2.10B	$2.05B	$1.99B	$1.96B	$1.84B	$1.82B	$5.95B	$1.81B	$1.87B	$1.82B	$5.41B	$5.54B	$5.59B	$5.40B	$4.92B	$5.20B	$5.03B	$4.72B	$4.35B	$4.40B	$4.25B	$4.18B	$4.54B	$3.85B	$3.69B
Low Forecast	$2.06B	$2.08B	$2.04B	$1.98B	$1.93B	$1.94B	$1.89B	$1.81B	$1.83B	$1.84B	$1.82B	$3.97B	$1.74B	$1.73B	$1.68B	$3.60B	$3.69B	$5.59B	$5.40B	$3.28B	$5.20B	$5.03B	$4.72B	$2.90B	$4.40B	$4.25B	$4.18B	$3.02B	$3.85B	$3.69B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	0.99%	0.81%	0.79%	1.06%	0.81%	0.78%	0.81%	1.08%	0.98%	1.25%	0.97%	1.00%	0.91%	0.93%

Elevance Health's average Quarter SG&A projection for Jun 23 is $1.76B, based on 9 Wall Street analysts, with a range of $1.68B to $1.82B. The forecast indicates a -63.31% fall compared to ELV last annual SG&A of $4.80B (Mar 23).

Elevance Health EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	6	6	12	11	10	9	8	13	14	9	6	6	12	9	9	9	5	5	5	5	6	6	6	6	10	10	10	10	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$3.63	$5.48	$7.83	$8.44	$3.99	$6.75	$6.87	$7.41	$4.65	$6.20	$7.33	$6.80	$2.25	$0.88	$9.02	$6.03	$3.69	$4.64
Avg Forecast	$5.93	$9.77	$11.95	$12.48	$5.48	$8.75	$10.07	$10.32	$3.98	$9.66	$10.00	$10.52	$5.60	$8.46	$8.78	$9.29	$5.19	$7.15	$7.75	$7.81	$5.11	$6.37	$6.34	$6.41	$2.53	$4.12	$8.74	$6.47	$3.88	$4.82
High Forecast	$6.20	$10.22	$12.50	$13.06	$5.74	$9.15	$10.54	$13.38	$6.59	$9.68	$10.00	$10.52	$5.67	$8.85	$9.19	$9.72	$5.43	$7.15	$7.75	$7.81	$5.11	$6.37	$6.34	$6.41	$2.53	$4.12	$8.74	$6.47	$3.88	$4.82
Low Forecast	$5.58	$9.19	$11.24	$11.74	$5.16	$8.23	$9.47	$8.02	$2.91	$9.63	$10.00	$10.52	$5.53	$7.96	$8.26	$8.74	$4.88	$7.15	$7.75	$7.81	$5.11	$6.37	$6.34	$6.41	$2.53	$4.12	$8.74	$6.47	$3.88	$4.82
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.65%	0.65%	0.89%	0.91%	0.77%	0.94%	0.89%	0.95%	0.91%	0.97%	1.16%	1.06%	0.89%	0.21%	1.03%	0.93%	0.95%	0.96%

According to 6 Wall Street analysts, Elevance Health's projected average Quarter EPS for Mar 24 is $10.52, with a low estimate of $10.52 and a high estimate of $10.52. This represents a 189.79% increase compared to ELV previous annual EPS of $3.63 (Dec 23).

Elevance Health Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CVS	CVS Health	$56.05	$98.50	75.74%	Buy
HUM	Humana	$271.35	$445.86	64.31%	Hold
CNC	Centene	$58.83	$92.20	56.72%	Buy
ELV	Elevance Health	$400.70	$538.74	34.45%	Buy
MOH	Molina Healthcare	$292.19	$349.38	19.57%	Hold
CI	Cigna	$322.45	$318.74	-1.15%	Buy
UNH	UnitedHealth Group	$589.65	$577.00	-2.15%	Buy
ALHC	Alignment Healthcare	$11.17	$9.50	-14.95%	Buy

ELV Forecast FAQ

Is Elevance Health a good buy?

Yes, according to 13 Wall Street analysts, Elevance Health (ELV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 92.31% of ELV's total ratings.

What is ELV's price target?

Elevance Health (ELV) average price target is $538.74 with a range of $335 to $643, implying a 34.45% from its last price of $400.7. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Elevance Health stock go up soon?

According to Wall Street analysts' prediction for ELV stock, the company can go up by 34.45% (from the last price of $400.7 to the average price target of $538.74), up by 60.47% based on the highest stock price target, and down by -16.40% based on the lowest stock price target.

Can Elevance Health stock reach $600?

ELV's highest twelve months analyst stock price target of $643 supports the claim that Elevance Health can reach $600 in the near future.

What is Elevance Health's current price target trend?

2 Wall Street analysts forecast a $522 price target for Elevance Health (ELV) this month, up 30.27% from its last price of $400.7. Compared to the last 3 and 12 months, the average price target increased by 31.10% and increased by 43.98%, respectively.

What are Elevance Health's analysts' financial forecasts?

Elevance Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $188.24B (high $194.88B, low $178.98B), average EBITDA is $11.5B (high $11.91B, low $10.94B), average net income is $8.07B (high $9.05B, low $7.2B), average SG&A $7.96B (high $8.24B, low $7.57B), and average EPS is $34.62 (high $38.81, low $30.87). ELV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $202.2B (high $209.42B, low $192.95B), average EBITDA is $12.36B (high $12.8B, low $11.79B), average net income is $9.35B (high $9.79B, low $8.8B), average SG&A $8.55B (high $8.86B, low $8.16B), and average EPS is $40.13 (high $41.99, low $37.74).

Did the ELV's actual financial results beat the analysts' financial forecasts?

Based on Elevance Health's last annual report (Dec 2023), the company's revenue was $171.34B, beating the average analysts forecast of $167.5B by 2.29%. Apple's EBITDA was $1.74B, missing the average prediction of $10.74B by -83.79%. The company's net income was $5.99B, missing the average estimation of $7.2B by -16.82%. Apple's SG&A was $0, missing the average forecast of $9.86B by -100.00%. Lastly, the company's EPS was $25.22, missing the average prediction of $32.13 by -21.51%. In terms of the last quarterly report (Dec 2023), Elevance Health's revenue was $42.65B, beating the average analysts' forecast of $42.19B by 1.09%. The company's EBITDA was $449M, missing the average prediction of $2.58B by -82.58%. Elevance Health's net income was $856M, missing the average estimation of $1.3B by -34.39%. The company's SG&A was $0, missing the average forecast of $1.78B by -100.00%. Lastly, the company's EPS was $3.63, missing the average prediction of $5.6 by -35.15%